The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study
P. van Valenberg, F. Johannes, van der Heijden, Antoine G., Cutie, Christopher J., Bhanvadia, Sumeet, Keegan, Kirk A., Hampras, Shalaka, Sweiti, Hussein, Maffeo, John C., Jin, Shu, Chau, Albert, Reynolds, Donald L., Iarossi, Crysti, Kelley, April, Li, Xiang, Stromberg, Katharine A., Michiel Sedelaar, J.P., Steenbruggen, Jessica J.O., Somford, Diederik M., Alfred Witjes, J.
Published in European urology open science (Online) (01.04.2024)
Published in European urology open science (Online) (01.04.2024)
Get full text
Journal Article
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
Park, Joon Oh, Feng, Yin-Hsun, Su, Wu-Chou, Oh, Do-Youn, Keam, Bhumsuk, Shen, Lin, Kim, Sang-We, Liu, Xiufeng, Liao, Huimin, Qing, Min, Zhang, Chong, Qian, Jiaqi, Tang, Xiaodan, Li, Peng, Triantos, Spyros, Sweiti, Hussein
Published in BMC cancer (13.08.2024)
Published in BMC cancer (13.08.2024)
Get full text
Journal Article
Adherence enhancing program for patients with metastatic, castration-resistant prostate carcinoma treated with abiraterone acetate plus prednisone: A cluster randomized trial
Suttmann, Henrik, Feyerabend, Susan, Gleissner, Jochen, Hübner, Andreas, Mathes, Tim, Baurecht, Werner, Krützfeldt, Katrin, Sweiti, Hussein
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial
Schuler, Martin H., Tabernero, Josep, Carranza, Omar, Loriot, Yohann, Pant, Shubham, Arnold, Dirk, Folprecht, Gunnar, Palmer, Daniel H., Prenen, Hans, Zibetti Dal Molin, Graziela, Lugowska, Iwona A., Cervantes, Andres, Sweiti, Hussein, Hammond, Constance, Najmi, Saltanat, Thomas, Shibu, Triantos, Spyros, Xia, Karen, Gutierrez, Martin
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies
Pant, Shubham, Park, Joon Oh, Su, Wu-Chou, Schuler, Martin H., Loriot, Yohann, Iyer, Gopa, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Prenen, Hans, Folprecht, Gunnar, Winter, Helen, Zibetti Dal Molin, Graziela, Sweiti, Hussein, Najmi, Saltanat, Hammond, Constance, Liao, Huimin, Thomas, Shibu, Triantos, Spyros, Feng, Yin-Hsun
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
P2-01 TAR-200 IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
Necchi, Andrea, Daneshmand, Siamak, Simone, Giuseppe, Xylinas, Evanguelos, Morris, David S., Zainfeld, Daniel, Kang, Taek Won, Matulay, Justin T., Belkoff, Laurence H., Decaestecker, Karel, Arentsen, Harm, Hampras, Shalaka, Cutie, Christopher J., Sweiti, Hussein, Stromberg, Katharine, Martin, Jason, Shukla, Abhijit, van der Heijden, Michiel S., Spiegelhalder, Philipp, Jacob, Joseph M.
Published in The Journal of urology (01.05.2024)
Published in The Journal of urology (01.05.2024)
Get full text
Journal Article
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study
Jacob, Joseph M, Guerrero-Ramos, Félix, Xylinas, Evanguelos, Simone, Giuseppe, Lotan, Yair, Pieczonka, Christopher Michael, Arentsen, Harm, Necchi, Andrea, Kulkarni, Girish S., Patel, Manish, Cahn, David J, Nam, Jong Kil, Boegemann, Martin, Hampras, Shalaka, Stromberg, Katherine, Martin, Jason L., Shulka, Abhijit, Sweiti, Hussein, Van Der Heijden, Michiel Simon
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor ( FGFR ) gene alterations: RAGNAR study pediatric cohort
Witt, Olaf, Geoerger, Birgit, Dirksen, Uta, Farouk Sait, Sameer, Reardon, David A., Shih, Kent C., Diez, Blanca D., Monteiro Caran, Eliana Maria, Karakawa, Shuhei, Stuyckens, Kim, Liao, Huimin, Najmi, Saltanat, Hammond, Constance, Santiago-Walker, Ademi E., Sweiti, Hussein
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL
Reardon, David, Welsh, Liam, Shih, Kent, Shimizu, Toshio, Goeminne, Jean-Charles, Geoerger, Birgit, Baldini, Capucine, Massard, Christophe, Loriot, Yohann, Pant, Shubham, Sait, Sameer Farouk, Thomas, Shibu, Hammond, Constance, Najmi, Saltant, Triantos, Spyros, Crow, Lauren, Sweiti, Hussein, Witt, Olaf
Published in Neuro-oncology (Charlottesville, Va.) (10.11.2023)
Published in Neuro-oncology (Charlottesville, Va.) (10.11.2023)
Get full text
Journal Article
Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations
Feng, Yin-Hsun, Su, Wu-Chou, Oh, Do-Youn, Shen, Lin, Kim, Kyu-Pyo, Liu, Xiufeng, Liao, Huimin, Qing, Min, Qian, Jiaqi, Triantos, Spyros, Sweiti, Hussein, Park, Joon Oh
Published in Journal of clinical oncology (01.02.2022)
Published in Journal of clinical oncology (01.02.2022)
Get full text
Journal Article
Tumour-agnostic efficacy and safety of erdafitinib in patients with advanced solid tumours with prespecified FGFR alterations: RAGNAR phase 2 study primary analysis
Pant, Shubham, Schuler, Martin, Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Reardon, David A, Massard, Christophe, Minchom, Anna, Lugowska, Iwona, Carranza, Omar, Arnold, Dirk, Gutierrez, Martin, Winter, Helen, Stuyckens, Kim, Crow, Lauren, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Santiago-Walker, Ademi, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann
Published in The lancet oncology (01.08.2023)
Published in The lancet oncology (01.08.2023)
Get full text
Journal Article
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations ( FGFRalt ): RAGNAR primary analysis
Pant, Shubham, Schuler, Martin H., Iyer, Gopa, Witt, Olaf, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Reardon, David A., Massard, Christophe, Welsh, Liam, Lugowska, Iwona A., Carranza, Omar, Stuyckens, Kim, Liao, Huimin, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE
Daneshmand, Siamak, van der Heijden, Michiel S, Jacob, Joseph M, Necchi, Andrea, Xylinas, Evanguelos, Morris, David S, Spiegelhalder, Philip, Zainfeld, Daniel, Kang, Taek Won, Matulay, Justin T, Belkoff, Laurence H, Decaestecker, Karel, Arentsen, Harm, Hampras, Shalaka, Jin, Shu, Cutie, Christopher J, Sweiti, Hussein, Stromberg, Katherine, Martin, Jason, Simone, Giuseppe
Published in The Journal of urology (01.04.2023)
Published in The Journal of urology (01.04.2023)
Get full text
Journal Article
Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study
van Valenberg, F. Johannes P., van der Heijden, Toine, Cutie, Christopher, Bhanvadia, Sumeet Kaur, Keegan, Kirk A., Hampras, Shalaka, Sweiti, Hussein, Maffeo, John, Jin, Shu, Chau, Albert, Reynolds, Don, Iarossi, Crysti, Kelley, April, Li, Xiang, Stromberg, Katherine, Sedelaar, Michiel, Steenbruggen, Jessica, Somford, Diederik Meindert, Witjes, Alfred Alfred
Published in Journal of clinical oncology (20.02.2023)
Published in Journal of clinical oncology (20.02.2023)
Get full text
Journal Article
Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations ( FGFRalt ) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results
Pant, Shubham, Schuler, Martin H., Iyer, Gopa, Doi, Toshihiko, Qin, Shukui, Tabernero, Josep, Arnold, Dirk, Gutierrez, Martin, Prenen, Hans, Folprecht, Gunnar, Winter, Helen, Cosman, Rasha, Zibetti Dal Molin, Graziela, Xia, Qi, Najmi, Saltanat, Hammond, Constance, Thomas, Shibu, Triantos, Spyros, Sweiti, Hussein, Loriot, Yohann
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR -inhibitor (FGFRi) erdafitinib
Massard, Christophe, Pant, Shubham, Iyer, Gopa, Schuler, Martin H., Witt, Olaf, Qin, Shukui, Tabernero, Josep, Doi, Toshihiko, Hargrave, Darren R., Hammond, Constance, Little, Shonda Marie, Xia, Qi, Cao, Jing, Santiago-Walker, Ademi E., Sweiti, Hussein
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article